scholarly journals Product of Serum Calcium and Phosphorus (Ca x Pi) as a Predictor of Cardiovascular Disease Risk in Patients with Chronic Kidney Disease

2020 ◽  
Vol 8 (1) ◽  
pp. 23-26
Author(s):  
Rojina Bakhunchhen ◽  
Raju Kumar Dubey ◽  
Archana Jayan ◽  
Santosh Kumar Shah ◽  
Prabin Khatri

INTRODUCTION: Most of the chronic kidney disease (CKD) patients develop cardiovascular disease (CVD) in their later stages. Various traditional CVD risk factors are highly prevalent in CKD but mortality of these patients cannot be fully justified by these CVD markers. So this study was designed to determine serum calcium and phosphorus product (Ca×Pi) to predict CVD risk in CKD patients. MATERIAL AND METHODS We followed the guidelines of NKF-KDOQI for CKD diagnosis and staging. Further the patients were classified into 3 different groups based on Ca×Pi product; <40 mg2/dl2 (group 1), 40-55 mg2/dl2 (group 2) and >55 mg2/dl2 (group 3). We then evaluated CVD risk by various traditional risk factors like age, BMI, BP, smoking history, dyslipidemia, previous history of CVD, LVH, arrhythmia, VHD, cardiomyopathy, and IHD. RESULTS: Higher level of Ca×Pi was associated with presence of LVH (32.30% in group 1, 31.42% in group 2 and 46.66% in group 3), Arrythemia (13.84% in group 1, 28.57% in group 2 and 46.67% in group 3), VHD (5.71% in group 2 and 10.00% in group 3), Cardiomyopathy (1.53% in group 1, 8.57% I group 2 and 6.66% in group 3), IHD (6.15% in group1, 11.42% in group 2 and 13.33% in group 3) and hypercholesterolemia, hypertriglyceridemia and increased LDLc. CONCLUSION: This study found that higher Ca×Pi increases with decline in glomerular filtration rate (GFR) and associated with CVD risks and CVD. So, this study raise a potential need to evaluate the level of calcium and phosphorus in all CKD patients and the level should be monitored more thoroughly to prevent CVD.

2018 ◽  
Vol 90 (9) ◽  
pp. 60-67 ◽  
Author(s):  
T E Rudenko ◽  
E S Kamyshova ◽  
M P Vasilyeva ◽  
I N Bobkova ◽  
N I Solomakhina ◽  
...  

Purpose of the study. To examine the frequency and risk factors for the development of diastolic dysfunction (DD) of the left ventricle (LV) of the heart in patients with chronic kidney disease (CKD). Materials and methods. The study included 225 patients with stage I-CKD of non-diabetic etiology (median age 47.0 years, 50.2% of women). Depending on the degree of decrease in the glomerular filtration rate (GFR), all patients were divided into 3 groups. Group 1 (n=70) consisted of patients with GFR 89-45 ml / min / 1.73 m2, group 2 (n=120) - patients with GFR 44-15 ml / min / 1.73 m2, group 3 (n=35) - patients with GFR


2015 ◽  
Vol 1 (1) ◽  
pp. 15-17
Author(s):  
Gobinda Chandra Saha ◽  
M Akhtaruzzaman ◽  
Ekramul Mustafa ◽  
Asif Mahmud ◽  
Sunil Kumar Sikder

Background: The progression of CKD occurs in five different stages in which there are gradual changes of GFR, serum creatinine and serum calcium.Objective: The study was undertaken to determine GFR in advanced stages of CKD and its relation with s. creatinine and s. calcium and also to find out the correlation between s. creatinine and s. calcium.Methodology: This study was carried out in the departments of Physiology and Nephrology, Rajshahi Medical College. All the advanced stage chronic kidney disease patients were taken as comparison. Apparently healthy persons were taken as control. Serum Creatinine was measured by alkaline picrate method; estimation of GFR was done by using Cockcroft- Gault formula and serum calcium was performed by analyzer.Result: In this study a total number of 120 subjects were included, out of which 30 were healthy control and 90 were diagnosed cases of advanced stages of CKD. Among the patients, 55 (61.12%) were male and 35 (38.88%) were female. Mean age (±SD) of the patients were 45 ± 11.16 (Range 20-65 years). While comparing between groups of CKD patients, it was found that s. creatinine of control group was significantly lower than that of group 1. Again s. creatinine of Group 1 was significantly lower than that of group 2 and similarly, s. creatinine of group 2 was significantly lower than that of group 3. On the other hand, s. calcium of control group was significantly higher than group 1, likewise s. calcium of group 1 was significantly higher than that of group 2 and s. calcium of group 2 was significantly higher than that of group 3.Conclusion: From this study the inference could be drawn that serum calcium had a positive correlation with GFR and a negative correlation with s. creatinine.J. Natl Inst. Neurosci Bangladesh 2015;1(1):15-17


Author(s):  
Tsuyoshi Yamabe ◽  
Yanling Zhao ◽  
Paul A Kurlansky ◽  
Suzuka Nitta ◽  
Saveliy Kelebeyev ◽  
...  

Abstract OBJECTIVES Chronic kidney disease (CKD) is prevalent in patients undergoing cardiovascular surgery, and it negatively impacts procedural outcomes; however, its influence on the outcomes of aortic surgery has not been well studied. This study aims to elucidate the importance of CKD on the outcomes of aortic root replacement (ARR). METHODS Patients who underwent ARR between 2005 and 2019 were retrospectively reviewed (n = 882). Patients were divided into 3 groups based on the Kidney Disease: Improving Global Outcomes criteria: Group 1 [estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73 m2, n = 421); Group 2 (eGFR = 30–59 ml/min/1.73 m2, n = 424); and Group 3 (eGFR &lt; 30 ml/min/1.73 m2, n = 37). To reduce potential confounding, a propensity score matching was also performed between Group 1 and the combined group of Group 2 and Group 3. The primary end point was 10-year survival. Secondary end points were in-hospital mortality and perioperative morbidity. RESULTS Severe CKD patients presented with more advanced overall chronic and acute illnesses. Kaplan–Meier analysis showed a significant correlation between CKD stage and 10-year survival (log-rank P &lt; 0.001). The number of events for Group 1 was 15, Group 2 was 49 and Group 3 was 11 in 10 years. Group 3 had significantly higher in-hospital mortality (13.5% vs 3.5% in Group 2 vs 0.7% in Group 1, P &lt; 0.001) and stroke (8.1% vs 7.1% vs 1.2%, P &lt; 0.001) as well as introduction to new dialysis (27.0% vs 5.4% vs 1.7%, P &lt; 0.001). eGFR was shown to be an independent predictor of mortality (hazard ratio, 0.98; 95% confidence interval, 0.96–0.99). Comparison between propensity matched groups showed similar postoperative outcomes, and eGFR was still identified as a predictor of mortality (hazard ratio, 0.97; 95% confidence interval, 0.95–0.99). CONCLUSIONS Higher stage in CKD negatively impacts the long-term survival in patients who are undergoing ARR.


2021 ◽  
pp. 75-76
Author(s):  
Bharat Bhushan ◽  
Debarshi Jana

Background: Dyslipidemia is very much common in chronic kidney disease patients and is responsible for cardiovascular disease (CKD) which is most common cause of mortality in them. So, it is necessary to study the lipid prole in CKD patients to prevent morbidity and mortality. Methods: Subjects each of 50 in number are grouped into healthy controls (group-1), CKD patients without hemodialysis (group-2), CKD patients with hemodialysis (group-3). After fasting of 12 hours, lipid prole is assessed in all cases. Results: In this study, there is increase in Total cholesterol (TC), Low Density lipoprotein (LDL), very Low-Density lipoprotein (VLDL) and Triglycerides (TG) and decrease in High Density Lipoprotein (HDL) in all CKD patients compared to healthy controls (p-value for each parameter <0.001). There is increase in TC, TG and VLDL in diabetic CKD patients compare to non-diabetic CKD patients and p-value for each parameter is <0.05. It was found that TG and VLDL increase and HDL decrease in group-3 compare to group-2 is statistically signicant (p-value for each <0.05) and no signicant variation in TC and LDL in these groups. Conclusions: Present study demonstrated that there is dyslipidemia in CKD patients irrespective of mode of management, but the derangement is much more common and signicant in CKD with hemodialysis group and they are at risk of cardiovascular disease. It is better to start lipid lowering drugs which decreases disease progression and dyslipidemia.


Author(s):  
David M Kern ◽  
Stephanie DeVore ◽  
Jennifer Kim ◽  
Ying Wu ◽  
Ozgur Tunceli ◽  
...  

CV events among T2DM patients are major contributors to high healthcare utilization and cost. Healthcare utilization and costs among T2DM patients with established CVD and CVD risk factors in a large US database were explored. T2DM patients aged ≥40 years were identified from the HealthCore Integrated Research Environment from 1/1/2007 to 4/30/2011 and followed from first T2DM diagnosis (index date) until loss of eligibility or death. Established CVD [Group 1] included patients with MI, stroke, peripheral vascular disease, coronary heart disease, congestive heart failure, or revascularization in the year prior to index. CVD risk [Group 2] included patients with older age (men ≥55 y, women ≥60 y) and prior diagnosis for either dyslipidemia or hypertension. Per person year (PPY) utilization and cost following T2DM diagnosis were calculated as the total number of events/cost divided by total number of person years of follow-up. There were 177,140 Group 1 (mean age: 68 y; 57% men) and 191,441 Group 2 (mean age: 66 y; 57% men) patients who met the selection criteria. During the 12, 24, 36, and 48 months following index, a higher proportion of Group 1 vs Group 2 patients had ≥1 inpatient visit (35%, 50%, 61%, 69% vs 16%, 27%, 36%, 44% respectively) and ≥1 ED visit (6.2%, 17%, 29%, 41% vs 2.9%, 9%, 18%, 28% respectively). T2DM patients have high healthcare utilization and costs. Those with established CVD have higher PPY event rates (Figure 1) and costs (Figure 2), compared with patients with CVD risk factors. Inpatient hospitalizations and outpatient visits are key cost drivers in this T2DM population.


Author(s):  
Н.С. Морозова ◽  
Н.Б. Захарова ◽  
Д.Ю. Лакомова ◽  
Л.Д. Мальцева ◽  
О.Л. Морозова

Изменения минерального гомеостаза являются причиной костных нарушений зубочелюстной системы (ЗЧС) при хронической болезни почек (ХБП) у детей и могут развиваться задолго до появления клинических проявлений уремической токсинемии на 2-й стадии ХБП. В последние годы большое внимание уделяется неинвазивным методам диагностики патологии полости рта у детей. Наиболее известными индикаторами нарушения костного метаболизма считают матриксную металлопротеиназу 8 (ММР-8) и остеопротогерин (OPG). Цель исследования - установить закономерности изменения содержания ММР-8 и OPG в слюне детей с различной тяжестью ХБП. Объект и методы. Проведено исследование содержания ММР-8 и OPG в слюне у 76 детей, которые были разделены на равные группы по 19 человек: 1 группа - дети с ХБП 1-2 степени, получающие медикаментозное лечение; 2 группа - дети с терминальной стадией ХБП, получающие заместительную почечную терапию в объёме гемодиализа; 3 группа - дети через год после перенесённой трансплантации почки; 4 группа (группа сравнения) - дети с малой хирургической патологией, не имеющие патологии почек. Сбор слюны осуществлялся абсорбционным методом до медикаментозной коррекции основного заболевания утром до приема пищи. Исследование ММР-8 и OPG проводили методом твердофазного иммуноферментного анализа. Результаты. Установлено, что содержание ММР-8 и OPG в слюне у детей с различной степенью ХБП было значительно выше по отношению к группе сравнения. Максимальные значения ММР-8 регистрировались во 2-й группе у детей с терминальной ХБП, находящихся на гемодиализе. Повышение содержания OPG в слюне отмечалось в 1 группе детей с ХБП 1-2-й степени и 3-й группе пациентов, через год после перенесённой трансплантации почки. Заключение. Полученные результаты показывают возможность использования слюны в качестве биологической жидкости для диагностики доклинических этапов нарушения костного метаболизма у детей с ХБП, а ММР-8 и OPG в слюне могут рассматриваться в качестве предиктивных и прогностических маркеров. Changes in mineral homeostasis cause bone disorders of the dentition in children with chronic kidney disease (CKD) and may develop long before the onset of clinical manifestations of uremic toxemia in stage 2 CKD. In recent years, much attention has been paid to noninvasive methods for diagnosing oral pathology in children. The most common indicators of metabolic bone disorders are matrix metalloproteinase-8 (MMP-8) and osteoprotogerin (OPG). The aim of the study was to establish the patterns of changes in salivary concentrations of MMP-8 and OPG in children with various severity of CKD. Subject and methods. Salivary levels of MMP-8 and OPG were studied in 76 children divided into four equal groups: group 1, children with stage 1-2 CKD receiving a drug treatment; group 2, children with end-stage CKD receiving renal replacement therapy with hemodialysis; group 3, children one year after the kidney transplantation; and group 4 (comparison group), children with a minor surgical pathology without a kidney pathology. Saliva samples were collected by the absorption method before administration of drugs for the underlying disease, one hour before the morning meal. Salivary concentrations of MMP-8 and OPG were measured by enzyme-linked immunosorbent assay. Results. Salivary levels of MMP-8 and OPG were significantly higher in children with various severity of CKD than in the comparison group. The highest values of MMP-8 were observed in group 2 children with end-stage CKD on hemodialysis. Increased salivary OPG was noted in group 1 children with stage 1-2 CKD and in group 3 patients one year after the kidney transplantation. Conclusion. Saliva can be used as a biological fluid for diagnosis of preclinical stages of bone metabolism disorders in children with CKD, and salivary MMP-8 and OPG can be considered as predictive and prognostic markers.


2021 ◽  
Author(s):  
Rajeev Kumar ◽  
Pratip Jana ◽  
Indu Priyadarshini ◽  
SMITA ROY ◽  
Pritha Dutta ◽  
...  

ABSTRACT INTRODUCTION The SARS-CoV-2 pandemic has emerged as perhaps the most challenging global health problem of this century. The concomitant presence of co morbidities like chronic kidney disease (CKD), diabetes, chronic heart disease etc. makes the task of patient management difficult. AIMS AND OBJECTIVES To assess the patterns of liver test abnormalities in patients of COVID 19 infection with and without CKD and evaluate the probable outcomes. MATERIALs and METHODS A cross-sectional retrospective observational study done on 600 patient samples (Group 1 COVID-19 without CKD, Group 2 COVID-19 with CKD and Group 3 non COVID-19 with CKD) which were processed for Liver function test (AST, ALT and ALP) and Renal function test (Urea and Creatinine) in the Department of Biochemistry, Dr. RML Hospital New Delhi. RESULTS AST and ALT levels were significantly higher (P < 0.05) in all COVID 19 positive patients group 1 mean and 2 SD, (63.63 and 42.89 U/L & 50.25 and 46.53 U/L respectively) and group 2 (90.59 and 62.51 U/L & 72.09 and 67.24 U/L respectively) as compared to Group 3 (25.24 and 7.47 U/L & 24.93 and 11.44 U/L respectively) and also a statistically significant elevation is seen in these two parameters (AST & ALT) in Group 2 as compared to Group 1 (P < 0.05). There was a negative significant correlation between eGFR and AST/ALT levels in Group 1 (p < 0.05). In Group 2, a weak positive correlation was seen with ALT (p < 0.01). No significant correlation existed between eGFR and ALP in groups 1 and 2. In Group 3, eGFR showed strong correlations with AST and ALT levels (p < 0.01) and reduction in kidney function correlated well with increase in serum ALP levels, (p < 0.01). CONCLUSIONS This study most comprehensively describes that SARS-CoV-2 positive CKD patients show more elevations in serum aminotransferase levels as compared to their non-CKD counterparts, in contrast to non-COVID-19 CKD cases. Serum ALT values in SARS-CoV-2 patients show significant correlation with calculated eGFR values. Elevated ALP values in CKD patients may be used as an indicator of declining kidney function. However, more studies in this direction are needed.


Author(s):  
Vetalise C Konje ◽  
Thekkelnaycke M Rajendiran ◽  
Keith Bellovich ◽  
Crystal A Gadegbeku ◽  
Debbie S Gipson ◽  
...  

Abstract Background Non-traditional risk factors like inflammation and oxidative stress play an essential role in the increased cardiovascular disease (CVD) risk prevalent in chronic kidney disease (CKD). Tryptophan catabolism by the kynurenine pathway (KP) is linked to systemic inflammation and CVD in the general and dialysis population. However, the relationship of KP to incident CVD in the CKD population is unknown. Methods We measured tryptophan metabolites using targeted mass spectrometry in 92 patients with a history of CVD (old CVD); 46 patients with no history of CVD and new CVD during follow-up (no CVD); and 46 patients with no CVD history who developed CVD in the median follow-up period of 2 years (incident CVD). Results The three groups are well-matched in age, gender, race, diabetes status and CKD stage, and only differed in total cholesterol and proteinuria. Tryptophan and kynurenine levels significantly decreased in patients with ‘Incident CVD’ compared with the no CVD or old CVD groups (P = 5.2E–7; P = 0.003 respectively). Kynurenic acid, 3-hydroxykynurenine and kynurenine are all increased with worsening CKD stage (P &lt; 0.05). An increase in tryptophan levels at baseline was associated with 0.32-fold lower odds of incident CVD (P = 0.000014) compared with the no CVD group even after adjustment for classic CVD risk factors. Addition of tryptophan and kynurenine levels to the receiver operating curve constructed from discriminant analysis predicting incident CVD using baseline clinical variables increased the area under the curve from 0.76 to 0.82 (P = 0.04). Conclusions In summary, our study demonstrates that low tryptophan levels are associated with incident CVD in CKD.


2018 ◽  
Vol 35 (5) ◽  
pp. 827-836 ◽  
Author(s):  
Cédric Villain ◽  
Marie Metzger ◽  
Christian Combe ◽  
Denis Fouque ◽  
Luc Frimat ◽  
...  

Abstract Background Although chronic kidney disease (CKD) and age are major risk factors for cardiovascular disease (CVD), little is known about the relative proportions of atheromatous and non-atheromatous CVD by age in CKD patients. Methods We used baseline data from the French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort of 3033 patients (65% men) with CKD Stages 3–4 to study crude and adjusted associations between age, the estimated glomerular filtration rate (eGFR), atheromatous CVD (coronary artery disease, peripheral artery disease and stroke) and non-atheromatous CVD (heart failure, cardiac arrhythmia and valvular heart disease). Results Mean age was 66.8 and mean Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR was 32.9 mL/min/1.73 m2. In the &lt;65, (65–74), (75–84) and ≥85 year age groups, the prevalence was, respectively, 18.7, 35.5, 42.9 and 37.8% for atheromatous CVD, and 14.9, 28.4, 38.1 and 56.4% for non-atheromatous CVD. After adjusting for albuminuria, sex and CVD risk factors, the odds ratio (OR) [95% confidence interval (CI)] for (65–74), (75–84) and ≥85 age groups (compared with the &lt;65 group) was, respectively, 1.99 (1.61–2.46), 2.89 (2.30–3.62), 2.72 (1.77–4.18) for atheromatous CVD and 2.07 (1.66–2.58), 3.15 (2.50–3.97), 7.04 (4.67–10.61) for non-atheromatous CVD. Compared with patients with an eGFR ≥30 mL/min/1.73 m2, those with an eGFR &lt;30 mL/min/1.73 m2 had a higher OR for atheromatous CVD [1.21 (1.01–1.44)] and non-atheromatous CVD [1.16 (0.97–1.38)]. Conclusions In this large cohort of CKD patients, both atheromatous and non-atheromatous CVD were highly prevalent and more frequent in older patients. In a given age group, the prevalence of atheromatous and non-atheromatous CVD was similar (except for a greater prevalence of non-atheromatous CVD after 85).


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
ALENA SAZONAVA ◽  
Tatiana Mokhort ◽  
Natalia Karlovich

Abstract Background and Aims Impaired thyroid function is a common endocrine pathology among patients with chronic kidney disease (CKD), affecting metabolic parameters, including iron metabolism. The purpose of the study was to investigate potential relationship between thyroid status and iron metabolism profile in patients with type 1 diabetes (T1D) and DKD. Method We recruited 155 patients with T1D. GFR was estimated by CKD-MDRD formula. All patients were divided into 3 groups: the group 1 comprised 59 patients with GFR&gt;60 ml/min; group 2-77 patients with GFR&lt;60 ml/min, group 3- 19 patients, receiving renal replacement therapy (RRT). Biochemical parameters, HbA1c, thyroid hormones, iron homeostasis parameters were measured. Nonparametric statistical methods were used. A P-value &lt;0,05 was considered significant. Results Groups were matched by age of T1D manifestation, HbA1c, BMI, CKD duration in groups 2 and 3. Duration of T1D differed by groups. Comparative analysis of patients in the subgroups revealed reliable differences in TSH levels only between patients from group 1 (p= 0.009), however, in the whole sample and in RRT patients its levels remained within the reference interval. Groups differed by FT4 values (group 1 - 14.12 (12.70-16.25) pmol / L, group 2 - 14.52 (13.27-16, 21), 3 group - 12.25 (11.38-13.48), p1,2 = 0.143, p1,3 = 0.035, p2,3 = 0.003) and FT3 (1 group - 4.43 (4,02-4.89) pmol / L, 2 group - 4.27 (3.98-4.78), 3 group - 1.43 (1.31-1.57), p1,2 = 0.712, p1,3 = 0.002, p2,3 = 0.012) with a tendency to maximum decrease when receiving RRT. No significant differences were obtained according to the levels of total T4 and T3, TG, Ab-TG, AbTPO. Significant decrease in Ab-R-TSH levels (group 1 - 0.70 (0.44-1.67) IU / l, group 2 - 0.40 (0.30-0.88), group 3 - 0.30 (0.30-0, 52), p1,2 = 0.492, p1,3 = 0.009, p2,3 = 0.035) confirms the absence of the influence of autoimmune component on the genesis of thyroid disorders in patients with CKD. No differences were obtained between groups in terms of serum iron levels and total iron binding capacity. Patients significantly differed in ERYTHROCYTES levels (group 1 - 4.68 (4.41-5.01) 109 / l, group 2 - 4.59 (3.96-4.83), group 3 - 3.84 (3, 32-4.27), p1,3 &lt;0.001, p2,3 &lt;0.001), HEMOGLOBIN (group 1 -139.00 (129.00-154.00), group 2 - 135, 00 (115.50-145.00), group 3 - 115.00 (103.00-124.00), p1,2 = 0.025, p1,3 &lt;0.001, p2,3 &lt;0.001), HCT (1 group - 41.90 (39.20-45.10)%, group 2 - 40.75 (35.65-43.70), group 3 - 36.25 (32.90-41.20), p1,3 &lt;0.001, p2,3 = 0.055), TRANSFERRIN (group 1 - 32.90 (30.80-35.60) μmol / L, group 2 - 31.60 (19.20-35, 45) 3 group - 2.45 (2.14-3.65), p1,2 = 0.049, p1,3 &lt;0.001, p2,3 &lt;0.001) and FERRITIN (1 group - 54.00 (33.00- 74.97) μg / L, group 2 - 74.85 (37.18-109.90), group 3 - 152.60 (92.80-329.60), p1,3 &lt; 0,001, p2,3 = 0.001), which reflects the highest sensitivity of these indicators to decrease in renal function. HCT correlated with levels of total T3 (ρ = 0.489), AbTPO (ρ = -0.490), total T4 (ρ = 0.536). Hb levels correlated with total T4 levels (ρ = 0.811), fT3 (ρ = 0.483). Ferritin levels correlated with fT4 (ρ = 0.510), and transferrin with fT3 (ρ = 0.523). Serum iron levels correlated with AbTPO (ρ = -0.656). Conclusion According to revealed changes, possibly anemia contributes to the development of thyroid dysfunctions in patients with diabetic genesis of CKD, due to the involvement of iron in the processes of deiodination and peripheral conversion of thyroid hormones.


Sign in / Sign up

Export Citation Format

Share Document